Not yet recruitingInterventionalPhase 2Last updated Aug 13, 2026

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

A Phase 2, Multicenter, Open Label, Parallel-Group Study of the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

Overview

ClinicalTrials.gov ID: NCT07762027
Lead Sponsor: Assembly BiosciencesINDUSTRY
Brief Summary: This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Oct 2026Estimated
Primary Completion Date: Jun 2027Estimated
Completion Date: Sep 2028Estimated

Study Record Dates

First Submitted: Aug 5, 2026
First Submitted that Met QC Criteria: Aug 7, 2026
First Posted: Aug 13, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 7, 2026
Last Update Posted: Aug 13, 2026Actual
Last Verified: Jul 2026

NCT06740474Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants

NCT06384131Completed

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection

NCT05414981Completed

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection

NCT03576066Completed

A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection

NCT04398134Terminated

A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

NCT02908191Completed

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B